Article

Navigating the commercialization of cell and gene therapies

This article was originally published on European Pharmaceutical Review (EPR) on May 19, 2025

Kevin Chinn, VP and Head of Cell and Gene Service Line at Cencora, talks about the hurdles to making cell and gene therapy a commercial success – and how to leap over them.

Read the article to explore the potential and major obstacles impacting cell and gene therapies in the pharmaceutical industry.

Pardot Form

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract

Related resources

The portraits of two subject matter experts are contained in bubbles. Between them is a speech bubble icon.

Story | Expanding access globally

Table Talk: Beyond the breakthrough
Learn more

Article

The JCA unleashed: Key takeaways and outlook from early reports
Learn more

Webinar

Building HTA‑ready evidence with AI‑enabled early modeling
Learn more